Anthrax countermeasures: Current status and future needs

Luciana L. Borio, Gigi Gronvall

Research output: Contribution to journalArticle

Abstract

The U.S. government does not yet have the range of medical countermeasures needed to protect its citizens from anthrax and other potential bioweapons. In the event of an anthrax attack, treatment interventions in addition to antibiotics would be needed so that very ill patients can be treated and clean-up crews can be better protected, especially if an engineered strain is used. This article describes specific anthrax countermeasures that are in development, barriers to development, and potential mechanisms the government could use to accelerate the movement of these countermeasures through the pipeline. A key challenge will be to encourage the transition of promising leads from basic research to the product development stage, when they may qualify for BioShield funds.

Original languageEnglish (US)
Pages (from-to)102-112
Number of pages11
JournalBiosecurity and Bioterrorism
Volume3
Issue number2
DOIs
StatePublished - Dec 1 2005
Externally publishedYes

Fingerprint

anthrax
Anthrax
Antibiotics
Product development
Pipelines
product development
basic research
Financial Management
antibiotics
Anti-Bacterial Agents
citizen
event
Research
need
Therapeutics

ASJC Scopus subject areas

  • Health(social science)
  • Medicine(all)
  • Public Health, Environmental and Occupational Health
  • Management, Monitoring, Policy and Law

Cite this

Anthrax countermeasures : Current status and future needs. / Borio, Luciana L.; Gronvall, Gigi.

In: Biosecurity and Bioterrorism, Vol. 3, No. 2, 01.12.2005, p. 102-112.

Research output: Contribution to journalArticle

@article{eec2fb9cbde5486f8c8e8dbec0075533,
title = "Anthrax countermeasures: Current status and future needs",
abstract = "The U.S. government does not yet have the range of medical countermeasures needed to protect its citizens from anthrax and other potential bioweapons. In the event of an anthrax attack, treatment interventions in addition to antibiotics would be needed so that very ill patients can be treated and clean-up crews can be better protected, especially if an engineered strain is used. This article describes specific anthrax countermeasures that are in development, barriers to development, and potential mechanisms the government could use to accelerate the movement of these countermeasures through the pipeline. A key challenge will be to encourage the transition of promising leads from basic research to the product development stage, when they may qualify for BioShield funds.",
author = "Borio, {Luciana L.} and Gigi Gronvall",
year = "2005",
month = "12",
day = "1",
doi = "10.1089/bsp.2005.3.102",
language = "English (US)",
volume = "3",
pages = "102--112",
journal = "Health security",
issn = "2326-5094",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Anthrax countermeasures

T2 - Current status and future needs

AU - Borio, Luciana L.

AU - Gronvall, Gigi

PY - 2005/12/1

Y1 - 2005/12/1

N2 - The U.S. government does not yet have the range of medical countermeasures needed to protect its citizens from anthrax and other potential bioweapons. In the event of an anthrax attack, treatment interventions in addition to antibiotics would be needed so that very ill patients can be treated and clean-up crews can be better protected, especially if an engineered strain is used. This article describes specific anthrax countermeasures that are in development, barriers to development, and potential mechanisms the government could use to accelerate the movement of these countermeasures through the pipeline. A key challenge will be to encourage the transition of promising leads from basic research to the product development stage, when they may qualify for BioShield funds.

AB - The U.S. government does not yet have the range of medical countermeasures needed to protect its citizens from anthrax and other potential bioweapons. In the event of an anthrax attack, treatment interventions in addition to antibiotics would be needed so that very ill patients can be treated and clean-up crews can be better protected, especially if an engineered strain is used. This article describes specific anthrax countermeasures that are in development, barriers to development, and potential mechanisms the government could use to accelerate the movement of these countermeasures through the pipeline. A key challenge will be to encourage the transition of promising leads from basic research to the product development stage, when they may qualify for BioShield funds.

UR - http://www.scopus.com/inward/record.url?scp=24644466890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24644466890&partnerID=8YFLogxK

U2 - 10.1089/bsp.2005.3.102

DO - 10.1089/bsp.2005.3.102

M3 - Article

C2 - 16000041

AN - SCOPUS:24644466890

VL - 3

SP - 102

EP - 112

JO - Health security

JF - Health security

SN - 2326-5094

IS - 2

ER -